prasad_raju_land

Raju Prasad

Analyst
+1 312 364 8469
Email vCard

Specialties:  Biotechnology

Raju Prasad, Ph.D., a biotechnology analyst focused on therapeutics, joined William Blair in March 2014. Dr. Prasad previously worked as a research associate with the University of North Carolina at Chapel Hill’s Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency. Dr. Prasad has a B.A. in cell biology and neuroscience from Rutgers University, an M.S. in exercise physiology from the University of Delaware, and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill with a focus in genetic toxicology and mutagenesis.

Initiation of Research Coverage of Two Gene Therapy Companies

William Blair & Company initiated research coverage of two gene therapy companies—Krystal Biotech, Inc. (KRYS $15.07) and Rocket Pharmaceuticals, Inc. (RCKT $19.17). Learn More

bluebird bio, Inc.: Initiation of Research Coverage

William Blair & Company initiated research coverage of bluebird bio, Inc. (BLUE $203.15), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. Learn More

Global Blood Therapeutics, Inc.: Initiation of Research Coverage

William Blair & Company initiated research coverage of Global Blood Therapeutics, Inc. (GBT $53.95), a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics to treat blood-based disorders with significant unmet medical need. Learn More